GRIN2A Recombinant Antibody

$Lane 1: Rat Brain; Probed with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.$

Lane 1: Rat Brain; Probed with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:1000 overnight at 4\u00b0C followed by a conjugated secondary antibody for 60 minutes at 37\u00b0C.

$Paraformaldehyde-fixed and paraffin-embedded Rat Brain tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Rat Brain tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Rat Skin tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Rat Skin tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Human Brain tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Human Brain tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

$Paraformaldehyde-fixed and paraffin-embedded Mouse Small Intestine tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.$

Paraformaldehyde-fixed and paraffin-embedded Mouse Small Intestine tissue incubated with GRIN2A (3C3) Monoclonal Antibody (bsm-54048R) at 1:100, overnight at 4\u00b0C, followed by a conjugated secondary antibody and DAB staining. Counterstained with hematoxylin.

Applications

WB
IHC-P

Reactivity

Human
Mouse
Rat

Overview
Catalog #	bsm-54048r-100ul
Product Name	GRIN2A Recombinant Antibody
Applications	WB, IHC-P
Reactivity	Human, Mouse, Rat
Specifications
Conjugation	Unconjugated
Host	Rabbit
Source	Human NMDAR1 aa 750-950
Clonality	Recombinant
Isotype	IgG
Concentration	1ug/ul
Purification	Purified by Protein A.
Storage Buffer	0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage Condition	Store for 1 year at -20°C from date of shipment. Store for 1 year at -20°C from date of shipment.
Target
Gene ID	2903
Swiss Prot	Q12879
Synonyms	Glutamate receptor ionotropic, NMDA 2AGlutamate [NMDA] receptor subunit epsilon-1, N-methyl D-aspartate receptor subtype 2A, GluN2A, NMDAR2A, NR2A, hNR2A, GRIN2A, NMDAR2A
Background	This gene encodes a member of the glutamate-gated ion channel protein family. The encoded protein is an N-methyl-D-aspartate (NMDA) receptor subunit. NMDA receptors are both ligand-gated and voltage-dependent, and are involved in long-term potentiation, an activity-dependent increase in the efficiency of synaptic transmission thought to underlie certain kinds of memory and learning. These receptors are permeable to calcium ions, and activation results in a calcium influx into post-synaptic cells, which results in the activation of several signaling cascades. Disruption of this gene is associated with focal epilepsy and speech disorder with or without mental retardation. Alternative splicing results in multiple transcript variants.
Application Dilution
WB	1:300-5000
IHC-P	1:200-400